Archives

– Targeting and Activating Dendritic Cells is the Key to Success

Leiden, The Netherlands, March 11, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has announced the publication of a review of cancer immunotherapies in Nature Reviews Cancer [1] that outlines strategies to overcome immune evasion by tumors. The publication was co-authored by a team of researchers from Leiden University Medical Center (LUMC) and ISA Pharmaceutical’s’ CSO Kees Melief.

Cancer immunotherapies have a mixed track record. While challenging the immune system via tumor antigens by raising tumor-specific T cells is successful in most cases, this strategy often does not cause T

– Seasoned executive brings over twenty years of commercial biotech and pharma experience

Leiden, The Netherlands, January 5, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that Gerben Moolhuizen has been appointed as the company´s Chief Business Development Officer (CBO).

Gerben Moolhuizen has over twenty years of experience in the pharmaceutical and biotechnology industry in various roles covering business development, product development and general management. His experience spans very diverse fields covering a broad array of technical areas (biopharmaceuticals, small molecules, drug delivery, pharmaceutical development and manufacturing, diagnostics,

– Trial in patients with HPV16-positive, incurable solid tumors initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb

Leiden, The Netherlands, December 7, 2015 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the start of a Phase II combination trial, which will be conducted at The University of Texas MD Anderson Cancer Center (Houston, TX).

The goal of the open-label Phase II study is to investigate whether a combination of ISA101 with Nivolumab can help to control cancer that has spread in the body. The

– Review in The Journal of Clinical Investigation points the way forward for therapeutic cancer vaccines

Leiden, The Netherlands, July 28, 2015 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the publication of a comprehensive scientific review [1]  of therapeutic cancer vaccines, outlining the best available strategies for successfully eradicating tumors with immunotherapy. The article, which was published in The Journal of Clinical Investigation, was authored by a group of scientists from Leiden University Medical Center (LUMC); lead author is Cornelis Melief, professor at LUMC and CSO

– Three additional European patents and market exclusivity granted for the use of key active ingredients of ISA101

Leiden, The Netherlands, June 23, 2015 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has strengthened the IP position of its lead compound ISA101. The European Patent Office has granted three patents (EP2267132, EP2112157, EP2468763) which relate to the use of HPV antigen-based peptides. ISA101, a novel immunotherapeutic consisting of synthetic long peptides (SLP®s), targets severe diseases triggered by human papillomavirus (HPV) infection.

The patents cover the application of a

– SLP®s modulate intratumoral macrophages required for tumor regression

Leiden, The Netherlands, May 12, 2015 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the publication of a new peer-reviewed paper* demonstrating a beneficial effect of Synthetic Long Peptide (SLP®s) immunotherapeutics on intratumoral macrophages in cancers induced by human papilloma virus 16 (HPV16). ISA’s proprietary SLP® immunotherapeutics are rationally designed, off-the-shelf, synthetic peptides which ISA is developing as cancer immunotherapeutics. The company’s SLP® lead compound ISA101 is in clinical development for the treatment of early-stage, advanced and recurrent cancers

– Intradermal administration provides significant benefits compared to subcutaneous application

Leiden, The Netherlands, March 24, 2015 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has been granted a European patent (patent no. EP 2 155 240) for the intradermal administration of synthetic long peptides (SLP®s) based on HPV oncogenes, including its lead compound ISA101.

Specifically, the patent was granted for the therapeutic use of intradermally delivered long peptides derived from the E2, E6 and/or E7 proteins of the human papillomavirus (HPV) to treat or prevent HPV-related diseases.

ISA101 is

– Experiments to evaluate a novel nasal cervical cancer immunotherapeutic

Leiden, The Netherlands, March 3, 2015 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that its fully-owned subsidiary ISA Therapeutics B.V. has closed an R&D agreement with Japan-based Shin Nippon Biomedical Laboratories, Ltd. (SNBL) to explore a novel nasal delivery for ISA’s cervical cancer immunotherapeutic. In the experiments, ISA Pharmaceuticals’ proprietary Synthetic Long Peptide (SLP®) immunotherapeutic ISA101 will be administered via SNBL’s novel nasal drug delivery technology. SNBL´s patent-protected approach is designed to significantly enhance the absorption of

– Leiden University Medical Center to study novel immunotherapeutic in HPV-positive head & neck cancer patients

Leiden, The Netherlands, February 26, 2015 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, has announced the start of an investigator-initiated Phase I/II clinical trial of a novel immunotherapeutic based on ISA Pharmaceuticals´ platform technology. The trial will be conducted by the Department of Clinical Oncology at Leiden University Medical Center in The Netherlands. The study will investigate the biological activity and safety of the compound in head and neck cancer patients who tested

– Synthetic Long Peptide (SLP®) immunotherapy achieves targeted tumor eradication comparable to checkpoint-blocking immunotherapy

– New findings on antigens relevant for checkpoint blocking pave the way for personalized cancer vaccines

Leiden, The Netherlands, November 27, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that a recent scientific paper in Nature supports the company´s therapeutic approach to using synthetic long peptides in cancer therapy. It could be shown that personalized SLP® immunotherapy is as capable of inducing efficient tumor eradication as are T cell checkpoint inhibitors such as